Courillon-Mallet A, Wautier J L
Arch Mal Coeur Vaiss. 1985 Dec;78 Spec No:63-8.
The discovery of thromboxanes and prostacycline has opened up a new therapeutic approach to vascular and thrombotic diseases. Aspirin is no longer considered to be an antiaggregant drug, but an inhibitor of cyclooxygenase which, depending on the dose, may have an effect on platelets and the vessel. Thromboxane synthetase inhibitors and thromboxane receptor blockers represent a new mode of inhibition of platelet activation. Therapeutic trials of the vasodilator and antiaggregant prostacycline have been carried out in obliterative arterial disease and Raynaud' syndrome with a certain degree of success. The production of a stable analogue of prostacycline and the manipulation of the leukotrienes are the therapeutic hopes for the future.
血栓素和前列环素的发现为血管疾病和血栓形成疾病开辟了一种新的治疗方法。阿司匹林不再被认为是一种抗聚集药物，而是一种环氧化酶抑制剂，根据剂量不同，它可能对血小板和血管产生影响。血栓素合成酶抑制剂和血栓素受体阻滞剂代表了抑制血小板活化的新模式。血管扩张剂和抗聚集剂前列环素已在闭塞性动脉疾病和雷诺综合征中进行了治疗试验，并取得了一定程度的成功。生产前列环素的稳定类似物以及对白三烯的调控是未来的治疗希望。
